keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/27913442/comparison-of-anti-vegf-therapies-on-fibrovascular-pigment-epithelial-detachments-in-age-related-macular-degeneration
#1
Adrian Au, Vishal S Parikh, Rishi P Singh, Justis P Ehlers, Alex Yuan, Aleksandra V Rachitskaya, Jonathan E Sears, Sunil K Srivastava, Peter K Kaiser, Andrew P Schachat, Daniel F Martin, Yasha Modi
BACKGROUND: The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD). METHODS: This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27907924/outcomes-when-switching-from-a-pro-re-nata-regimen-to-a-treat-and-extend-regimen-using-aflibercept-in-neovascular-age-related-macular-degeneration
#2
Helena Giannakaki-Zimmermann, Andreas Ebneter, Marion R Munk, Sebastian Wolf, Martin S Zinkernagel
PURPOSE: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. PROCEDURE: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed...
December 2, 2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27902539/cystoid-macular-edema-and-cystoid-macular-degeneration-as-a-result-of-multiple-pathogenic-factors-in-the-setting-of-central-serous-chorioretinopathy
#3
Polina Astroz, Chandrakumar Balaratnasingam, Lawrence A Yannuzzi
PURPOSE: To report the pathogenic factors that account for cystoid macular edema and cystoid macular degeneration in chronic central serous chorioretinopathy (CSC). METHODS: The clinical course and multimodal imaging findings, including fundus color photography, fundus autofluorescence, spectral-domain optical coherence tomography, and fluorescein angiography, of one eye with cystoid macular edema due to chronic CSC was documented. RESULTS: A 44-year old woman with a history of chronic CSC presented with progressive visual decline in the right eye...
November 29, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27899972/efficacy-and-safety-of-aflibercept-in-metastatic-colorectal-cancer-pretreated-with-bevacizumab-a-report-of-five-cases
#4
Julia Alcaide, Mayte Delgado, Marta Legerén, José Miguel Jurado, Isabel Blancas, Teresa Pereda, Jorge López, Margarita Garrido, María J Sánchez, José L García, Antonio Rueda
Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27890437/trends-of-anti-vascular-endothelial-growth-factor-use-in-ophthalmology-among-privately-insured-and-medicare-advantage-patients
#5
Ravi Parikh, Joseph S Ross, Lindsey R Sangaralingham, Ron A Adelman, Nilay D Shah, Andrew J Barkmeier
PURPOSE: To characterize the first 10 years of intravitreal anti-vascular endothelial growth factor (VEGF) medication use for ophthalmic disease, including bevacizumab, ranibizumab, and aflibercept. DESIGN: A retrospective cohort study using administrative claims data from January 1, 2006 to December 31, 2015. SUBJECTS: Total of 124 835 patients 18 years of age or over in the United States. METHODS: OptumLabs Data Warehouse, which includes administrative claims data for over 100 million commercially insured and Medicare Advantage individuals, was used to identify patients receiving intravitreal anti-VEGF injections based on Current Procedural Terminology codes...
November 24, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27888621/intraperitoneal-ziv-aflibercept-effectively-manages-refractory-ascites-in-colorectal-cancer-patients
#6
Chieh-Sheng Lu, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Hao-Wei Teng
Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patients who did not respond to standard chemotherapy. Fifty or 100 mg of ziv-aflibercept in 100 mL of saline solution were infused through a pigtail catheter and retained for 24 h. When the ascites drainage volumes were subsequently monitored, 73...
November 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27886182/vitreous-levels-of-placental-growth-factor-correlate-with-activity-of-proliferative-diabetic-retinopathy-and-are-not-influenced-by-bevacizumab-treatment
#7
E Al Kahtani, Z Xu, S Al Rashaed, L Wu, A Mahale, J Tian, E B Abboud, N G Ghazi, I Kozak, V Gupta, J F Arevalo, E J Duh
PurposePlacental growth factor (PlGF) is a member of the VEGF family that plays an important role in experimental models of diabetic retinopathy and retinal neovascularization. We aimed to investigate whether vitreous levels of PlGF correlated with proliferative diabetic retinopathy (PDR) status, VEGF levels, and bevacizumab treatment. We also analysed PDR membranes to confirm the presence of the PlGF receptor, FLT1, in endothelial cells.MethodsThis was a case-control study: undiluted vitreous fluid samples were obtained from 28 active PDR patients without preoperative bevacizumab treatment, 21 active PDR patients with preoperative bevacizumab treatment, 18 inactive PDR patients, and 21 control patients...
November 25, 2016: Eye
https://www.readbyqxmd.com/read/27881184/stereotactic-radiotherapy-for-wet-age-related-macular-degeneration-star-study-protocol-for-a-randomised-controlled-clinical-trial
#8
James E Neffendorf, Riti Desai, Yanzhong Wang, Joanna Kelly, Caroline Murphy, Barnaby C Reeves, Usha Chakravarthy, Sarah Wordsworth, Cornelius Lewis, Janet Peacock, Shahir Uddin, Joe M O'Sullivan, Timothy L Jackson
BACKGROUND: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF). The most commonly used anti-VEGF drugs are ranibizumab, bevacizumab and aflibercept. The main objective of the STAR trial is to determine if stereotactic radiotherapy can reduce the number of anti-VEGF injections that patients with nAMD require. METHODS/DESIGN: STAR is a multicentre, double-masked, randomised, sham-controlled clinical trial...
November 24, 2016: Trials
https://www.readbyqxmd.com/read/27878592/high-frequency-aflibercept-injections-in-persistent-neovascular-age-related-macular-degeneration
#9
Ilkay Kilic Muftuoglu, Frank F Tsai, Raouf Gaber, Mostafa Alam, Amit Meshi, William R Freeman
PURPOSE: To report the 1-year outcomes of every-4-weeks (Q4W) as-needed aflibercept treatment in resistant neovascular age-related macular degeneration (nAMD) patients who had been treated and failed prior bevacizumab or ranibizumab injections, and who also responded poorly to every-8-weeks (Q8W) aflibercept treatment. METHODS: Forty-three eyes of 39 patients with persistent nAMD despite monthly bevacizumab and/or ranibizumab injections and who were switched to Q8W 2-mg aflibercept injections, but showed persistence of fluid were included...
November 23, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#10
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
November 15, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27855459/-port-catheter-associated-superior-vena-cava-syndrome-in-a-patient-with-rectum-cancer
#11
Nikolai Schuelper, Jakob von Herder, Antonius Flohr, Gerald Wulf, Sabine Blaschke
History and clinical findings | A 59-year-old man with metastasized rectum cancer presents at the interdisciplinary emergency care unit with a distinct cyanosis of his face. At that moment the patient himself is out of any complaints. Cyanosis is spreading from his face over his neck to both arms. During the last months he has been treated with folinic acid, 5-fluoruracil, irinotecan and aflibercept via a port-catheter. Except for smoking his further medical history is unremarkable. Examinations | CT-scan shows a port-catheter associated thrombosis with a consecutive superior vena cava syndrome (SCVS)...
November 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27853350/intravitreal-aflibercept-for-the-treatment-of-choroidal-neovascularization-associated-with-pathologic-myopia-a-pilot-study
#12
Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova
PURPOSE: To determine the efficacy of intravitreal aflibercept injections for the treatment of patients with choroidal neovascularization (CNV) associated with pathologic myopia. METHODS: In this uncontrolled, prospective cohort study, 31 eyes of 30 consecutive patients affected by CNV associated with pathologic myopia were treated with intravitreal aflibercept (2 mg) as needed following two initial monthly doses and observed over a 12-month follow-up period. The primary endpoint was change in best-corrected visual acuity (BCVA) at month 12, while central retinal thickness (CRT) on optical coherence tomography (OCT), neovascularization activity on fluorescein angiography, the number of aflibercept injections administered, and safety were examined as secondary endpoints...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27848983/treatment-of-polypoidal-choroidal-vasculopathy-by-photodynamic-therapy-aflibercept-and-dexamethasone-triple-therapy
#13
Mary Ho, Donald C F Woo, Vesta C K Chan, Alvin L Young, Marten E Brelen
Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naïve polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported...
November 16, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27847638/aflibercept-in-branch-retinal-vein-occlusion-as-second-line-therapy-clinical-outcome-12%C3%A2-months-after-changing-treatment-from-bevacizumab-ranibizumab-a-pilot-study
#14
Magdalena A Wirth, Matthias D Becker, Nicole Graf, Stephan Michels
PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients (n = 10) with chronic macular edema secondary to BRVO were included in a retrospective analysis. These patients received aflibercept after an insufficient response to treatment with ranibizumab and/- or bevacizumab...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847634/initiation-of-intravitreal-aflibercept-injection-treatment-in-patients-with-diabetic-macular-edema-a-review-of-vivid-dme-and-vista-dme-data
#15
Focke Ziemssen, Patricio G Schlottman, Jennifer I Lim, Hansjürgen Agostini, Gabriele E Lang, Francesco Bandello
BACKGROUND: Diabetic macular edema (DME) shows a gradual and sustained functional and morphologic response to anti-vascular endothelial growth factor (VEGF) drugs, but the optimal schedule for initiation of anti-VEGF therapy is not known. This study evaluates the treatment response behavior of DME in the Phase 3 trials of intravitreal aflibercept, with 5 initial intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4), in the upload phase. METHODS: This post hoc pooled analysis of the VISTA-DME (NCT01363440) and VIVID-DME (NCT01331681) trials evaluated the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) during the upload phase, using pooled data from both IAI treatment groups [2q4 and 2 mg every 8 weeks (2q8)]...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847621/fusion-proteins-for-treatment-of-retinal-diseases-aflibercept-ziv-aflibercept-and-conbercept
#16
REVIEW
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847620/conversion-back-to-bevacizumab-or-ranibizumab-for-recurrent-neovascular-activity-with-aflibercept-in-age-related-macular-degeneration-a-case-series
#17
Geraldine R Slean, Kornwipa Hemarat, Rahul N Khurana, Jay M Stewart
BACKGROUND: Neovascular age-related macular degeneration often requires chronic therapy with anti-VEGF agents, and patients with recurrent disease are challenging to manage. METHODS: This retrospective case series evaluates patients who were switched from bevacizumab or ranibizumab to aflibercept and then back again because of recurrent fluid on optical coherence tomography (OCT) by reporting changes in OCT measurements over the course of medication changes. RESULTS: Twenty-one eyes in nineteen patients received an average of 20...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27836572/neonatal-fc-receptor-fcrn-is-involved-in-intracellular-transport-of-the-fc-fusion-protein-aflibercept-and-its-transition-through-retinal-endothelial-cells
#18
Heidrun L Deissler, Gerhard K Lang, Gabriele E Lang
Retinal endothelial cells (REC) likely contribute to the clearance of intravitreally injected IgG. Because this is of high relevance to the pharmacokinetic assessment of the widely used therapeutic Fc fusion protein aflibercept, we studied its transport through immortalized bovine REC (iBREC) in detail. For shuttling of IgG or Fc fusion proteins like aflibercept, endothelial cells use the highly conserved neonatal Fc receptor (FcRn) also expressed in iBREC where it is down regulated by serum depletion. Therefore, we focused on studying intracellular localization and transport of aflibercept under conditions affecting its interaction with the FcRn...
November 9, 2016: Experimental Eye Research
https://www.readbyqxmd.com/read/27833450/the-era-of-anti-vascular-endothelial-growth-factor-vegf-drugs-in-ophthalmology-vegf-and-anti-vegf-therapy
#19
REVIEW
Dorota Pożarowska, Piotr Pożarowski
Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are involved in new vessel formation in embryogenesis and maturation, as well as in reparative or pathological reactions in later stages. They play a substantial role in regeneration, inflammation, wound healing, as well as in cancer pathology...
2016: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/27827554/differential-effects-of-bevacizumab-ranibizumab-and-aflibercept-on-the-viability-and-wound-healing-of-corneal-epithelial-cells
#20
Seungbum Kang, Hyunsu Choi, Chang Rae Rho
PURPOSE: This study compared the effects of 3 antivascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab, and aflibercept) on corneal epithelial cell viability and wound healing using human corneal epithelial cells (HCECs). METHODS: To determine the cytotoxic effects of anti-VEGF agents on HCECs, HCEC viability was determined at various concentrations of these agents. An in vitro migration assay was used to investigate the migration of HCECs treated with 3 anti-VEGF agents...
December 2016: Journal of Ocular Pharmacology and Therapeutics
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"